<a href=Novo Nordisk‘s diabetes research centre in Seattle, US.” height=”178″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/static-progressive/NovoDiabetes.jpg” width=”300″ />

Denmark-based pharmaceutical company Novo Nordisk is to create a research and development centre in Seattle, US, for type 1 diabetes, in order to further research into a disease that the company claims has been neglected.

The centre is due to be opened later this year and will employ 20 researchers, tasked with conducting basic research and early proof-of-concept trials in order provide the necessary foundation to push early-stage discoveries from animal models and into clinical exploratory trials. It will be located on the same site as the company’s inflammation research centre in order to boost synergies between the two fields of research.

Upon announcing the research facility, Novo Nordisk claimed that type 2 diabetes, the more common variant of the disease, has become the main focus for pharmaceutical companies because of the rise of people suffering from the disease in recent times.

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard said, "It is our mission to take type 1 diabetes research to the next level. With the new type 1 diabetes R&D centre, we hope to accelerate the process of finding new, innovative ways of treating people with this disease."

Of the 366 million people living with diabetes in 2011, it is estimated that just 5-10% of these suffer from the type 1 strain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Caption: Novo Nordisk’s diabetes research centre in Seattle, US. Image courtesy of: Novo Nordisk.